Serum Cancer Biomarkers

Serum Cancer Biomarkers Comprehensive Study by Type (Hepatocellular Carcinoma Serum Biomarkers, Lung Cancer Serum Biomarkers, Pancreatic and Biliary Tract Cancer Serum Biomarkers, Breast Cancer Serum Biomarkers, Glioblastoma Serum Biomarkers, Others), Application (Hospitals, Academic and Research Institutes, Ambulatory Surgical Centers, Others), Technology (Omics Technologies, Imaging Technologies, Mammography, Bioinformatics) Players and Region - Global Market Outlook to 2026

Serum Cancer Biomarkers Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Serum Cancer Biomarkers Market?

Serum cancer biomarkers refer to a substance or process that is indicative of the presence of cancer in the body. They are biological molecules that suggest the presence of cancer in a patient. They are either produced by the cancer cells or by noncancer cells in response to cancer. Cancer biomarkers identified from serum are the most desirable form of the biomarkers that can be used for personalized daily care in screening, diagnosis, establishing prognosis, monitoring treatment, and detecting relapse.

The market study is being classified by Type (Hepatocellular Carcinoma Serum Biomarkers, Lung Cancer Serum Biomarkers, Pancreatic and Biliary Tract Cancer Serum Biomarkers, Breast Cancer Serum Biomarkers, Glioblastoma Serum Biomarkers and Others), by Application (Hospitals, Academic and Research Institutes, Ambulatory Surgical Centers and Others) and major geographies with country level break-up.

Thermo Fisher Scientific (United States), Bio-Rad Laboratories, Inc. (United States), Roche Diagnostics (Switzerland), Qiagen N.V. (Germany), Illumina (United States), GE Healthcare (United States), Agilent Technologies (United States), Biomérieux SA (France), Merck & Co. (United States) and Abbott Laboratories (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Becton, Dickinson and Company (United States), Danaher Corporation (United States), Myriad Genetics (United States), Sysmex Corporation (Japan), Hologic (United States) and Quest Diagnostics (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Serum Cancer Biomarkers market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Serum Cancer Biomarkers market by Type, Application and Region.

On the basis of geography, the market of Serum Cancer Biomarkers has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Cancer Disease
  • Rising Use of Cancer Biomarkers in Drug Discovery and Development
  • Development of New Diagnostic Centre and Hospitals

Market Trend
  • Technological Advancements in the Field of Medical Science

Restraints
  • Unfavorable Regulatory and Reimbursement Scenario

Opportunities
  • Development of Healthcare Infrastructure in Emerging Economies
  • Growing Focus on Preventive Healthcare

Challenges
  • Proving Clinical Validity and Utility of Biomarker-Based Tests





Key Target Audience
Research Professionals, Emerging Companies, Government Body & Associations and End-user

Report Objectives / Segmentation Covered

By Type
  • Hepatocellular Carcinoma Serum Biomarkers
  • Lung Cancer Serum Biomarkers
  • Pancreatic and Biliary Tract Cancer Serum Biomarkers
  • Breast Cancer Serum Biomarkers
  • Glioblastoma Serum Biomarkers
  • Others
By Application
  • Hospitals
  • Academic and Research Institutes
  • Ambulatory Surgical Centers
  • Others
By Technology
  • Omics Technologies
  • Imaging Technologies
  • Mammography
  • Bioinformatics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cancer Disease
      • 3.2.2. Rising Use of Cancer Biomarkers in Drug Discovery and Development
      • 3.2.3. Development of New Diagnostic Centre and Hospitals
    • 3.3. Market Challenges
      • 3.3.1. Proving Clinical Validity and Utility of Biomarker-Based Tests
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Field of Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Serum Cancer Biomarkers, by Type, Application, Technology and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Serum Cancer Biomarkers (Value)
      • 5.2.1. Global Serum Cancer Biomarkers by: Type (Value)
        • 5.2.1.1. Hepatocellular Carcinoma Serum Biomarkers
        • 5.2.1.2. Lung Cancer Serum Biomarkers
        • 5.2.1.3. Pancreatic and Biliary Tract Cancer Serum Biomarkers
        • 5.2.1.4. Breast Cancer Serum Biomarkers
        • 5.2.1.5. Glioblastoma Serum Biomarkers
        • 5.2.1.6. Others
      • 5.2.2. Global Serum Cancer Biomarkers by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Academic and Research Institutes
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Serum Cancer Biomarkers by: Technology (Value)
        • 5.2.3.1. Omics Technologies
        • 5.2.3.2. Imaging Technologies
        • 5.2.3.3. Mammography
        • 5.2.3.4. Bioinformatics
      • 5.2.4. Global Serum Cancer Biomarkers Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Serum Cancer Biomarkers (Price)
      • 5.3.1. Global Serum Cancer Biomarkers by: Type (Price)
  • 6. Serum Cancer Biomarkers: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Diagnostics (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Qiagen N.V. (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Illumina (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GE Healthcare (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Agilent Technologies (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biomérieux SA (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Serum Cancer Biomarkers Sale, by Type, Application, Technology and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Serum Cancer Biomarkers (Value)
      • 7.2.1. Global Serum Cancer Biomarkers by: Type (Value)
        • 7.2.1.1. Hepatocellular Carcinoma Serum Biomarkers
        • 7.2.1.2. Lung Cancer Serum Biomarkers
        • 7.2.1.3. Pancreatic and Biliary Tract Cancer Serum Biomarkers
        • 7.2.1.4. Breast Cancer Serum Biomarkers
        • 7.2.1.5. Glioblastoma Serum Biomarkers
        • 7.2.1.6. Others
      • 7.2.2. Global Serum Cancer Biomarkers by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Academic and Research Institutes
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Serum Cancer Biomarkers by: Technology (Value)
        • 7.2.3.1. Omics Technologies
        • 7.2.3.2. Imaging Technologies
        • 7.2.3.3. Mammography
        • 7.2.3.4. Bioinformatics
      • 7.2.4. Global Serum Cancer Biomarkers Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Serum Cancer Biomarkers (Price)
      • 7.3.1. Global Serum Cancer Biomarkers by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Serum Cancer Biomarkers: by Type(USD Million)
  • Table 2. Serum Cancer Biomarkers Hepatocellular Carcinoma Serum Biomarkers , by Region USD Million (2015-2020)
  • Table 3. Serum Cancer Biomarkers Lung Cancer Serum Biomarkers , by Region USD Million (2015-2020)
  • Table 4. Serum Cancer Biomarkers Pancreatic and Biliary Tract Cancer Serum Biomarkers , by Region USD Million (2015-2020)
  • Table 5. Serum Cancer Biomarkers Breast Cancer Serum Biomarkers , by Region USD Million (2015-2020)
  • Table 6. Serum Cancer Biomarkers Glioblastoma Serum Biomarkers , by Region USD Million (2015-2020)
  • Table 7. Serum Cancer Biomarkers Others , by Region USD Million (2015-2020)
  • Table 8. Serum Cancer Biomarkers: by Application(USD Million)
  • Table 9. Serum Cancer Biomarkers Hospitals , by Region USD Million (2015-2020)
  • Table 10. Serum Cancer Biomarkers Academic and Research Institutes , by Region USD Million (2015-2020)
  • Table 11. Serum Cancer Biomarkers Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 12. Serum Cancer Biomarkers Others , by Region USD Million (2015-2020)
  • Table 13. Serum Cancer Biomarkers: by Technology(USD Million)
  • Table 14. Serum Cancer Biomarkers Omics Technologies , by Region USD Million (2015-2020)
  • Table 15. Serum Cancer Biomarkers Imaging Technologies , by Region USD Million (2015-2020)
  • Table 16. Serum Cancer Biomarkers Mammography , by Region USD Million (2015-2020)
  • Table 17. Serum Cancer Biomarkers Bioinformatics , by Region USD Million (2015-2020)
  • Table 18. South America Serum Cancer Biomarkers, by Country USD Million (2015-2020)
  • Table 19. South America Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 20. South America Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 21. South America Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 22. Brazil Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 23. Brazil Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 24. Brazil Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 25. Argentina Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 26. Argentina Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 27. Argentina Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 28. Rest of South America Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 31. Asia Pacific Serum Cancer Biomarkers, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 35. China Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 36. China Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 37. China Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 38. Japan Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 39. Japan Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 40. Japan Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 41. India Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 42. India Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 43. India Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 44. South Korea Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 45. South Korea Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 46. South Korea Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 47. Taiwan Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 48. Taiwan Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 49. Taiwan Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 50. Australia Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 51. Australia Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 52. Australia Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 56. Europe Serum Cancer Biomarkers, by Country USD Million (2015-2020)
  • Table 57. Europe Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 58. Europe Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 59. Europe Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 60. Germany Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 61. Germany Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 62. Germany Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 63. France Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 64. France Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 65. France Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 66. Italy Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 67. Italy Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 68. Italy Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 69. United Kingdom Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 70. United Kingdom Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 71. United Kingdom Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 72. Netherlands Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 73. Netherlands Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 74. Netherlands Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 75. Rest of Europe Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 76. Rest of Europe Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 77. Rest of Europe Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 78. MEA Serum Cancer Biomarkers, by Country USD Million (2015-2020)
  • Table 79. MEA Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 80. MEA Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 81. MEA Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 82. Middle East Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 83. Middle East Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 84. Middle East Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 85. Africa Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 86. Africa Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 87. Africa Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 88. North America Serum Cancer Biomarkers, by Country USD Million (2015-2020)
  • Table 89. North America Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 90. North America Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 91. North America Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 92. United States Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 93. United States Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 94. United States Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 95. Canada Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 96. Canada Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 97. Canada Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 98. Mexico Serum Cancer Biomarkers, by Type USD Million (2015-2020)
  • Table 99. Mexico Serum Cancer Biomarkers, by Application USD Million (2015-2020)
  • Table 100. Mexico Serum Cancer Biomarkers, by Technology USD Million (2015-2020)
  • Table 101. Serum Cancer Biomarkers: by Type(USD/Units)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Serum Cancer Biomarkers: by Type(USD Million)
  • Table 113. Serum Cancer Biomarkers Hepatocellular Carcinoma Serum Biomarkers , by Region USD Million (2021-2026)
  • Table 114. Serum Cancer Biomarkers Lung Cancer Serum Biomarkers , by Region USD Million (2021-2026)
  • Table 115. Serum Cancer Biomarkers Pancreatic and Biliary Tract Cancer Serum Biomarkers , by Region USD Million (2021-2026)
  • Table 116. Serum Cancer Biomarkers Breast Cancer Serum Biomarkers , by Region USD Million (2021-2026)
  • Table 117. Serum Cancer Biomarkers Glioblastoma Serum Biomarkers , by Region USD Million (2021-2026)
  • Table 118. Serum Cancer Biomarkers Others , by Region USD Million (2021-2026)
  • Table 119. Serum Cancer Biomarkers: by Application(USD Million)
  • Table 120. Serum Cancer Biomarkers Hospitals , by Region USD Million (2021-2026)
  • Table 121. Serum Cancer Biomarkers Academic and Research Institutes , by Region USD Million (2021-2026)
  • Table 122. Serum Cancer Biomarkers Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 123. Serum Cancer Biomarkers Others , by Region USD Million (2021-2026)
  • Table 124. Serum Cancer Biomarkers: by Technology(USD Million)
  • Table 125. Serum Cancer Biomarkers Omics Technologies , by Region USD Million (2021-2026)
  • Table 126. Serum Cancer Biomarkers Imaging Technologies , by Region USD Million (2021-2026)
  • Table 127. Serum Cancer Biomarkers Mammography , by Region USD Million (2021-2026)
  • Table 128. Serum Cancer Biomarkers Bioinformatics , by Region USD Million (2021-2026)
  • Table 129. South America Serum Cancer Biomarkers, by Country USD Million (2021-2026)
  • Table 130. South America Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 131. South America Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 132. South America Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 133. Brazil Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 134. Brazil Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 135. Brazil Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 136. Argentina Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 137. Argentina Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 138. Argentina Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 139. Rest of South America Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 140. Rest of South America Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 141. Rest of South America Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 142. Asia Pacific Serum Cancer Biomarkers, by Country USD Million (2021-2026)
  • Table 143. Asia Pacific Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 144. Asia Pacific Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 145. Asia Pacific Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 146. China Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 147. China Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 148. China Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 149. Japan Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 150. Japan Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 151. Japan Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 152. India Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 153. India Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 154. India Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 155. South Korea Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 156. South Korea Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 157. South Korea Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 158. Taiwan Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 159. Taiwan Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 160. Taiwan Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 161. Australia Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 162. Australia Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 163. Australia Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 166. Rest of Asia-Pacific Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 167. Europe Serum Cancer Biomarkers, by Country USD Million (2021-2026)
  • Table 168. Europe Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 169. Europe Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 170. Europe Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 171. Germany Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 172. Germany Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 173. Germany Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 174. France Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 175. France Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 176. France Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 177. Italy Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 178. Italy Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 179. Italy Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 180. United Kingdom Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 181. United Kingdom Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 182. United Kingdom Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 183. Netherlands Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 184. Netherlands Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 185. Netherlands Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 186. Rest of Europe Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 187. Rest of Europe Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 188. Rest of Europe Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 189. MEA Serum Cancer Biomarkers, by Country USD Million (2021-2026)
  • Table 190. MEA Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 191. MEA Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 192. MEA Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 193. Middle East Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 194. Middle East Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 195. Middle East Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 196. Africa Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 197. Africa Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 198. Africa Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 199. North America Serum Cancer Biomarkers, by Country USD Million (2021-2026)
  • Table 200. North America Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 201. North America Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 202. North America Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 203. United States Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 204. United States Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 205. United States Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 206. Canada Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 207. Canada Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 208. Canada Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 209. Mexico Serum Cancer Biomarkers, by Type USD Million (2021-2026)
  • Table 210. Mexico Serum Cancer Biomarkers, by Application USD Million (2021-2026)
  • Table 211. Mexico Serum Cancer Biomarkers, by Technology USD Million (2021-2026)
  • Table 212. Serum Cancer Biomarkers: by Type(USD/Units)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Serum Cancer Biomarkers: by Type USD Million (2015-2020)
  • Figure 5. Global Serum Cancer Biomarkers: by Application USD Million (2015-2020)
  • Figure 6. Global Serum Cancer Biomarkers: by Technology USD Million (2015-2020)
  • Figure 7. South America Serum Cancer Biomarkers Share (%), by Country
  • Figure 8. Asia Pacific Serum Cancer Biomarkers Share (%), by Country
  • Figure 9. Europe Serum Cancer Biomarkers Share (%), by Country
  • Figure 10. MEA Serum Cancer Biomarkers Share (%), by Country
  • Figure 11. North America Serum Cancer Biomarkers Share (%), by Country
  • Figure 12. Global Serum Cancer Biomarkers: by Type USD/Units (2015-2020)
  • Figure 13. Global Serum Cancer Biomarkers share by Players 2020 (%)
  • Figure 14. Global Serum Cancer Biomarkers share by Players (Top 3) 2020(%)
  • Figure 15. Global Serum Cancer Biomarkers share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 19. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Roche Diagnostics (Switzerland) Revenue: by Geography 2020
  • Figure 23. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Qiagen N.V. (Germany) Revenue: by Geography 2020
  • Figure 25. Illumina (United States) Revenue, Net Income and Gross profit
  • Figure 26. Illumina (United States) Revenue: by Geography 2020
  • Figure 27. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 28. GE Healthcare (United States) Revenue: by Geography 2020
  • Figure 29. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 30. Agilent Technologies (United States) Revenue: by Geography 2020
  • Figure 31. Biomérieux SA (France) Revenue, Net Income and Gross profit
  • Figure 32. Biomérieux SA (France) Revenue: by Geography 2020
  • Figure 33. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 35. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 37. Global Serum Cancer Biomarkers: by Type USD Million (2021-2026)
  • Figure 38. Global Serum Cancer Biomarkers: by Application USD Million (2021-2026)
  • Figure 39. Global Serum Cancer Biomarkers: by Technology USD Million (2021-2026)
  • Figure 40. South America Serum Cancer Biomarkers Share (%), by Country
  • Figure 41. Asia Pacific Serum Cancer Biomarkers Share (%), by Country
  • Figure 42. Europe Serum Cancer Biomarkers Share (%), by Country
  • Figure 43. MEA Serum Cancer Biomarkers Share (%), by Country
  • Figure 44. North America Serum Cancer Biomarkers Share (%), by Country
  • Figure 45. Global Serum Cancer Biomarkers: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • Roche Diagnostics (Switzerland)
  • Qiagen N.V. (Germany)
  • Illumina (United States)
  • GE Healthcare (United States)
  • Agilent Technologies (United States)
  • Biomérieux SA (France)
  • Merck & Co. (United States)
  • Abbott Laboratories (United States)
Additional players considered in the study are as follows:
Becton, Dickinson and Company (United States) , Danaher Corporation (United States) , Myriad Genetics (United States) , Sysmex Corporation (Japan) , Hologic (United States) , Quest Diagnostics (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 244 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Serum Cancer Biomarkers Quantitative research analysis
Serum Cancer Biomarkers Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Cancer Disease " is seen as one of major growth factors of Serum Cancer Biomarkers Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Serum Cancer Biomarkers Market in coming years.

Know More About Serum Cancer Biomarkers Report?

Have a Query? Click Here

Other Related Reports

Medical Oxygen Concentrators Comprehensive Study by Type (Portable Oxygen Concentrators, Stationary Oxygen Concentrators), Application (Hospitals, Home Care, Ambulatory Surgical Centers), Technology ...
$ 3450
Advanced Remote Patient Monitoring Systems Comprehensive Study by Type (Blood Pressure Cuff., Glucometer., Pulse Oximeter., ECG + Stethoscope., Thermometer., Scale., Others), Application (Managing di...
$ 3800
Cardiac Imaging Comprehensive Study by Type (X-Rays, Ultrasound (Echocardiograms), CT (Computed Tomography) Scans, MRI (Magnetic Resonance Imaging) Scans, Coronary Catheterization, Positron Emission ...
$ 3650
Transcriptomics Comprehensive Study by Type (Microarray, Real-time PCR, Sequencing Technology (Sanger Sequencing, RNA-Sequencing)), Application (Diagnostics & Disease Profiling, Drug Discovery, Other...
$ 3750
Text Healthcare Analytics Comprehensive Study by Type (Software, Services), Application (Customer experience management, Marketing management, Governance, Risk and compliance management), Industry (P...
$ 3750
ABPM Patient Monitors Comprehensive Study by Type (General Type, Wearable Type), Device (Arm ABPM Devices, Wrist ABPM Devices), End-User (Hospital & Clinic, Emergency Services, Diagnostics Laborato...
$ 3500